TMB-2

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

Retrieved on: 
Monday, November 29, 2021
Synthase, Biology, Doctor of Philosophy, Legislation, GLOBE, Dietary supplement, NLC, Immune system, SPAC, Drug development, Infection, Cell cycle, COVID, IP, CEO, TMB-2, Pressure, School, Time, Brain, Lymphocyte, Cancer, Alzheimer's disease, TBIA, Research, Science, Social media, T cell, Method, Coronavirus, IPO, Solution, Therapy, Vaccine, U.S. Securities and Exchange Commission, Omicron, OTCQB, Airport, Apoptosis, Patient, Neuron, Technology, Industry, Monocyte, Acquisition, MERS, Plasma, PCR, Neurodegeneration, Computer, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Quarantine, Knowledge, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has entered into a binding agreement to acquire all 3CL protease biology-related assets owned by NLC Pharma and form a majority-owned subsidiary called 3CL Sciences (“3CL Sciences”). 3CL Sciences will be focused on developing therapeutics, diagnostics and dietary supplements based on the pioneering 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology work of Dorit Arad, PhD, who will be appointed Chief Scientific Officer of the new company. We believe this acquisition will solidify Todos Medical’s position as a key player in the development and commercialization of 3CL protease-related products. These products currently include Tollovir®, a therapeutic drug candidate for the treatment of COVID-19 and other nidovirus coronaviruses, TolloTest ™, a diagnostic testing platform to identify the presence of the 3CL protease related to SARS-CoV-2, and Tollovid® & Tollovid Daily™, 3CL protease inhibitor dietary supplements that support and maintain healthy immune function. Additionally, the acquisition gives Todos Medical access to discoveries made by Dr. Arad related to the development and commercialization of new chemical entities targeting the 3CL protease and other mechanisms critical for the treatment of COVID-19 using her ‘mechanism-based design’ approach, as well as new designs for mass-scale deployment of the TolloTest technology.

Key Points: 
  • We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.
  • Under the terms of the agreement, Todos Medical will own 60% of 3CL Sciences, and the shareholders of NLC Pharma will own 40% upon the execution of definitive agreements (the Closing) to acquire all intellectual property and assets related to 3CL protease biology-related products to which NLC Pharma has rights.
  • Todos Medical will assign its European licensing agreement T-Cell Hellas Protect S.A. to 3CL Sciences.
  • Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria.

DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe

Retrieved on: 
Wednesday, November 24, 2021
Synthase, Emergency Use Authorization, European Economic Area, Company, Legislation, Biotechnology, Dietary supplement, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Time, Brain, Lymphocyte, Distribution, Alzheimer's disease, TBIA, Research, T cell, Method, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, Pharmaceutical industry, Security (finance), Vaccine, Animal, Medical imaging, Tollovid(R) & Tollovid Daily(TM), Tollovir(R), T-Cell Protect Hellas S.A., Todos Medical Ltd., TOLLOVID(R) & TOLLOVID DAILY(TM), TOLLOVIR(R), T-CELL PROTECT HELLAS S.A., TODOS MEDICAL LTD.

New York, NY, and Tel Aviv, ISRAEL - via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, Ltd., today announced that it has entered into an exclusive European licensing & distribution agreement with T-Cell Protect Hellas S.A. (T-Cell Protect or T-Cell) for a product based on its Tollovid(R) and Tollovid Daily(TM) 3CL protease inhibitor and immune support dietary supplements. The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months. T-Cell has placed an initial purchase order for 50,000 bottles of the Tollovid Daily product that is expected to meet the demand of an initial rollout to a subset of the 11,000 stores located throughout Greece. More information about the product can be found at www.tcellprotect.com. Under the terms of the agreement, T-Cell Protect will purchase finished product at wholesale from Todos until such time as T-Cell Protect establishes manufacturing capabilities at a facility it currently operates in Greece to support the European market. At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect. The Company anticipates revenue to be generated from this agreement beginning in the current quarter.

Key Points: 
  • Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
    The issuer is solely responsible for the content of this announcement.
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • "We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products," said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

Retrieved on: 
Wednesday, November 24, 2021
Biotechnology, Health, Oncology, Medical Devices, Patient, Synthase, Neuron, Apoptosis, TMB-2, CEO, Cancer, Pressure, Emergency Use Authorization, Technology, Time, Industry, MERS, Monocyte, Company, Brain, Lymphocyte, PCR, Plasma, Neurodegeneration, European Economic Area, Severe acute respiratory syndrome coronavirus 2, Solution, Cancer immunotherapy, Alzheimer's disease, COVID-19, TBIA, Legislation, U.S. Securities and Exchange Commission, Medicine, Research, Biotechnology, Dietary supplement, OTCQB, Knowledge, T cell, Immune system, Method, Cell cycle, COVID, Vaccine, Pharmaceutical industry, Animal, Medical imaging, Tollovid® & Tollovid Daily™, Tollovir®, T-Cell Protect Hellas S.A., Todos Medical Ltd., TOLLOVID® & TOLLOVID DAILY™, TOLLOVIR®, T-CELL PROTECT HELLAS S.A., TODOS MEDICAL LTD.

The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.

Key Points: 
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • The potential for Tollovid and Tollovid Daily in Europe is quite significant and we are excited to bring them to market.
  • We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products, said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece

Retrieved on: 
Monday, November 22, 2021
Synthase, Company, Legislation, Todos, GLOBE, Biotechnology, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Brain, Lymphocyte, Alzheimer's disease, TBIA, Research, T cell, Method, Coronavirus, Partnership, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, US Foods, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, Vaccine, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today announced it has received an initial purchase order from its European distribution partner T-Cell Protect Hellas S.A. (“T-Cell Protect” or “T-Cell”) for fifty thousand (50,000) bottles of its Tollovid Daily™ dietary supplement formulated product to be marketed under the T-Cell Protect brand (www.tcellprotect.com). The initial 50,000-bottle purchase order is expected to give T-Cell Protect a sufficient amount of product to complete its initial planned roll-out of T-Cell Protect to a subset of its 11,000 store retail distribution network throughout Greece, while also providing T-Cell Protect with sufficient marketing information to evaluate the relative number of maximum strength Tollovid® bottles it will need to purchase to fulfill demand for the Greek market for the first half of 2022. T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.

Key Points: 
  • T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.
  • Our initial focus is to conduct a targeted launch that aims to optimize marketing for the eight (8) largest countries in Europe before expanding throughout the continent.
  • The potential for Tollovid and Tollovid Daily in Europe is quite significant.
  • Tollovid Daily is a twice daily immune support product that is designed to provide ongoing daily immune support for the person on the go.

Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients

Retrieved on: 
Friday, November 19, 2021
Patient, Synthase, Neuron, Apoptosis, Coronavirus, TMB-2, Cancer, Pressure, Technology, Monocyte, MERS, Brain, Company, Lymphocyte, PCR, Plasma, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, Alzheimer's disease, COVID-19, TBIA, Legislation, U.S. Securities and Exchange Commission, Research, Biotechnology, OTCQB, Knowledge, Immune system, Method, Cell cycle, COVID, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today is very pleased announce an update regarding the ongoing clinical development of Tollovir®, a oral antiviral 3CL protease (3CLpro, Main protease, Mpro, Nsp5) inhibitor & anti-cytokine therapeutic candidate for the treatment of COVID-19. The enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel, Shaare Zedek Medical Center in Jerusalem and Hillel Yaffe Medical Center in Hadera, to allow for an interim analysis of the data. The Company expects data from the interim analysis to be reviewed by the trial Data Safety and Monitoring Board (DSMB) in the fourth quarter of 2021.

Key Points: 
  • Tollovir is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E.
  • Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity.
  • Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe

Retrieved on: 
Thursday, November 18, 2021
Synthase, Emergency Use Authorization, European Economic Area, Company, Legislation, GLOBE, Biotechnology, Dietary supplement, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Time, Â, Brain, Lymphocyte, Alzheimer's disease, TBIA, Research, TEL, T cell, Method, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, NEW, Pharmaceutical industry, Medical imaging

The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.

Key Points: 
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • The Company anticipates revenue to be generated from this agreement beginning in the current quarter.
  • We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products, said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test

Retrieved on: 
Wednesday, November 17, 2021
Serum, Synthase, Neuron, Apoptosis, Coronavirus, TMB-2, Federal Food, Drug, and Cosmetic Act, Pressure, Cancer, Emergency Use Authorization, Technology, Monocyte, Brain, Company, Lymphocyte, Plasma, PCR, News, Diagnosis, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Virus, Cancer prevention, Solution, Laboratory, Alzheimer's disease, COVID-19, Legislation, TBIA, U.S. Securities and Exchange Commission, Research, GLOBE, Biotechnology, OTCQB, Knowledge, FDA, EDTA, Cheddar (TV channel), Immune system, Infection, EUA, Method, Cell cycle, Animal, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the United States Food & Drug Administration has reauthorized the Emergency Use Authorization (EUA) for the cPass neutralizing antibody test (“cPass”)*. The new indication for cPass now reads:

Key Points: 
  • The new indication for cPass now reads:
    Qualitative and semi-quantitative direct detection of total neutralizing antibodies to SARS-CoV-2 in human serum and dipotassium EDTA plasma.
  • Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
  • Concurrent with this announcement, the Company announced that CEO Gerald Commissiong is to appear on Cheddar News at 6:10pm tonight, November 17th, 2021.
  • This test has been authorized only for the presence of total neutralizing antibodies against SARS-CoV-2, not for any other viruses or pathogens.

Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results

Retrieved on: 
Tuesday, November 16, 2021
Vizient, Inc., CRO, Treatment of cancer, PCR, COVID-19, Cancer, Acquisition, Solution, Season, COVID 19, Amazon, Alzheimer's disease, Legislation, Protease, Safety, Plasma, TBIA, Method, Technology, IPR, Automation, Research, Grant Thornton International, Shaare Zedek Medical Center, NLC, Biotechnology, Lymphocyte, Marketing, Patient, Brain, Pressure, Neurodegeneration, Knowledge, Disease, CPA, Synthase, CFS, Todos, Sale, Apoptosis, OTCQB, TMB-2, Neuron, Monocyte, Immune system, Pfizer, Severe acute respiratory syndrome coronavirus 2, Company, Breast cancer, Dietary supplement, Cell cycle, CFO, Pharmaceutical industry, Medical imaging

Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos Medical and NLC Pharma.

Key Points: 
  • Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos Medical and NLC Pharma.
  • Todos expects to provide interim data results in the fourth quarter of 2021.
  • Revenues: Total revenue in the third quarter of 2021 was$1.01 million vs. revenues of $1.28 million in 2021.
  • Loss from Operations: The Company recorded an operating loss of$(2,497,000)in the third quarter of 2021 compared to an operating loss of$(10,246,000)in the third quarter of 2020.

Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests

Retrieved on: 
Tuesday, November 16, 2021
Industry, Vizient, Inc., Cancer biomarker, PCR, RPP, COVID-19, Cancer, Acquisition, Solution, Collection, Alzheimer's disease, Legislation, Safety, Plasma, CLIA, TBIA, Method, Technology, The New Client, Research, NLC, Biotechnology, Lymphocyte, GLOBE, Patient, Brain, Pressure, U.S. Securities and Exchange Commission, CEO, Neurodegeneration, Knowledge, Synthase, COVID, Todos, International joint venture, Apoptosis, OTCQB, TMB-2, Nursing, Neuron, Monocyte, Immune system, Company, Cell cycle, Pharmaceutical industry, Medical imaging

Provista will be providing COVID PCR, cPass Neutralizing Antibody and Respiratory Pathogen Panel (RPP) testing with local sample collection expected to yield less than 12-hour turnaround times.

Key Points: 
  • Provista will be providing COVID PCR, cPass Neutralizing Antibody and Respiratory Pathogen Panel (RPP) testing with local sample collection expected to yield less than 12-hour turnaround times.
  • The Company expects to initially add 2,000 COVID PCR tests monthly, and increase the overall production on a monthly basis.
  • Additionally, the New Client already services skilled nursing and long-term care facilities that are looking to add the cPass neutralizing antibody testing into their health & safety protocols for residents and staff.
  • As we move into the holiday traveling season with falling temperatures that lead people indoors, the PCR COVID, cPass, and RPP testing panel have become critically important tests.

Todos Medical Reports Third Quarter 2021 Business and Financial Results

Retrieved on: 
Tuesday, November 16, 2021
Vizient, Inc., CRO, Treatment of cancer, PCR, COVID-19, Cancer, Acquisition, Solution, Season, COVID 19, Amazon, Alzheimer's disease, Legislation, Protease, Safety, Plasma, TBIA, Method, Technology, IPR, Automation, Research, Grant Thornton International, Shaare Zedek Medical Center, NLC, Biotechnology, Lymphocyte, Marketing, Patient, Brain, Pressure, Neurodegeneration, Knowledge, Disease, CPA, Synthase, CFS, International joint venture, Sale, Apoptosis, OTCQB, TMB-2, Neuron, Monocyte, Immune system, Pfizer, Severe acute respiratory syndrome coronavirus 2, Company, Breast cancer, Dietary supplement, Cell cycle, CFO, Pharmaceutical industry, Medical imaging

Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos Medical and NLC Pharma.

Key Points: 
  • Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos Medical and NLC Pharma.
  • Todos expects to provide interim data results in the fourth quarter of 2021.
  • Revenues: Total revenue in the third quarter of 2021 was$1.01 million vs. revenues of $1.28 million in 2021.
  • Loss from Operations: The Company recorded an operating loss of$(2,497,000)in the third quarter of 2021 compared to an operating loss of$(10,246,000)in the third quarter of 2020.